Based on the key indicators related to Summit Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Summit Therapeutics PLC is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Summit Therapeutics' Common Stock Shares Outstanding is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 213.1 M in 2024, despite the fact that Retained Earnings are likely to grow to (943.6 M). Key indicators impacting Summit Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Summit Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Summit Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Summit Therapeutics.
Please note, the imprecision that can be found in Summit Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Summit Therapeutics PLC. Check Summit Therapeutics' Beneish M Score to see the likelihood of Summit Therapeutics' management manipulating its earnings.
Summit Therapeutics Stock Summary
Summit Therapeutics competes with Nkarta, Cullinan Oncology, Kezar Life, Kronos Bio, and ZyVersa Therapeutics. Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. The company was founded in 2003 and is based in Cambridge, Massachusetts. Summit Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Summit Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Summit Therapeutics's current stock value. Our valuation model uses many indicators to compare Summit Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Summit Therapeutics competition to find correlations between indicators driving Summit Therapeutics's intrinsic value. More Info.
Summit Therapeutics PLC is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Summit Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Summit Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Summit Therapeutics PLC Systematic Risk
Summit Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Summit Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Summit Therapeutics PLC correlated with the market. If Beta is less than 0 Summit Therapeutics generally moves in the opposite direction as compared to the market. If Summit Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Summit Therapeutics PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Summit Therapeutics is generally in the same direction as the market. If Beta > 1 Summit Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Summit Therapeutics Thematic Clasifications
Summit Therapeutics PLC is part of several thematic ideas from Biotech to Israel Wall Street. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Summit Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Summit Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Summit Therapeutics growth as a starting point in their analysis.
Summit Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Summit Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Summit Therapeutics PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Summit Therapeutics PLC based on widely used predictive technical indicators. In general, we focus on analyzing Summit Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Summit Therapeutics's daily price indicators and compare them against related drivers.
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.